Autocrine VEGF Signaling Is Required for Vascular Homeostasis

Cell

Volumn 130, Issue 4, 2007, Pages 691-703

  Lee, Sunyoung ^a   Chen, Tom T ^a   Barber, Chad L ^a   Jordan, Maria C ^a   Murdock, Jared ^a   Desai, Sharina ^a   Ferrara, Napoleone ^b   Nagy, Andras ^c   Roos, Kenneth P ^a   Iruela Arispe, M Luisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

CELLBIO; DEVBIO; HUMDISEASE

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BLOOD VESSEL; CONTROLLED STUDY; GENE DELETION; HOMEOSTASIS; MOUSE; MOUSE MUTANT; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUDDEN DEATH; VASCULAR ENDOTHELIUM; WILD TYPE;

MUS;

EID: 34547941252     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2007.06.054     Document Type: Article

References (42)

1. Alva J.A., Zovein A.C., Monvoisin A., Murphy T., Salazar A., Harvey N.L., Carmeliet P., and Iruela-Arispe M.L. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev. Dyn. 235 (2006) 759-767
2. Betsholtz C., Westermark B., Ek B., and Heldin C.H. Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation. Cell 30 (1984) 447-457
3. Blann A.D. How a damaged blood vessel wall contibutes to thrombosis and hypertenasion. Pathophysiol. Haemost. Thromb. 33 (2003) 445-448
4. Bokel C., Schwabedissen A., Entchev E., Renaud O., and Gonzalez-Gaitan M. Sara endosomes and the maintenance of Dpp signaling levels across mitosis. Science 314 (2006) 1135-1139
5. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
6. Childress J.L., Acar M., Tao C., and Halder G. Lethal giant discs, a novel C2-domain protein, restricts notch activation during endocytosis. Curr. Biol. 16 (2006) 2228-2233
7. Choy J.C., Granville D.J., Hunt D.W., and McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J. Mol. Cell. Cardiol. 33 (2001) 1673-1690
8. Cohen S., and Fava R.A. Internalization of functional epidermal growth factor:receptor/kinase complexes in A-431 cells. J. Biol. Chem. 260 (1985) 12351-12358
9. Damert A., Miquerol L., Gertsenstein M., Risau W., and Nagy A. Insufficient VEGFA activity in yolk sac endoderm compromises haematopoietic and endothelial differentiation. Development 129 (2002) 1881-1892
10. Dvorak H.F. Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312 (2006) 522-526
11. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
12. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
13. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
14. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007) 273-286
15. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., Wright B.D., Radtke F., Aguet M., and Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 126 (1999) 1149-1159
16. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., Hong K., Marsters J.C., and Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
17. Gerhardt H., Ruhrberg C., Abramsson A., Fujisawa H., Shima D., and Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev. Dyn. 231 (2004) 503-509
18. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
19. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
20. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., Hu-Lowe D.D., Shalinsky D.R., Thurston G., Yancopoulos G.D., and McDonald D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165 (2004) 35-52
21. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
22. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3 (2006) 24-40
23. Jordan M.C., Zheng Y., Ryazantsev S., Rozengurt N., Roos K.P., and Neufeld E.F. Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol. Genet. Metab. 86 (2005) 233-243
24. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 60-65
25. Kamba T., Tam B.Y., Hashizume H., Haskell A., Sennino B., Mancuso M.R., Norberg S.M., O'Brien S.M., Davis R.B., Gowen L.C., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H560-H576
26. Lampugnani M.G., Orsenigo F., Gagliani M.C., Tacchetti C., and Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174 (2006) 593-604
27. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169 (2005) 681-691
28. Maharaj A.S., Saint-Geniez M., Maldonado A.E., and D'Amore P.A. Vascular endothelial growth factor localization in the adult. Am. J. Pathol. 168 (2006) 639-648
29. Miquerol L., Gertsenstein M., Harpal K., Rossant J., and Nagy A. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev. Biol. 212 (1999) 307-322
30. Miquerol L., Langille B.L., and Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127 (2000) 3941-3946
31. Mustonen T., and Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 129 (1995) 895-898
32. Namiki A., Brogi E., Kearney M., Kim E.A., Wu T., Couffinhal T., Varticovski L., and Isner J.M. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J. Biol. Chem. 270 (1995) 31189-31195
33. Oganesian A., Au S., Horst J.A., Holzhausen L.C., Macy A.J., Pace J.M., and Bornstein P. The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function. J. Biol. Chem. 281 (2006) 38507-38518
34. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
35. Seto E.S., and Bellen H.J. Internalization is required for proper Wingless signaling in Drosophila melanogaster. J. Cell Biol. 173 (2006) 95-106
36. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
37. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21 (1999) 70-71
38. Sporn M.B., and Todaro G.J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303 (1980) 878-880
39. van der Goot F.G., and Gruenberg J. Intra-endosomal membrane traffic. Trends Cell Biol. 16 (2006) 514-521
40. van Gaal W.J., West N., and Banning A.P. Myocardial infarction caused by distal embolisation of a ruptured left main plaque. Heart 92 (2006) 1101
41. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 (2004) 145-147
42. Zeng H., Dvorak H.F., and Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 276 (2001) 26969-26979